Hypoxia-induced responses by endothelial colony-forming cells are modulated by placental growth factor
- 926 Downloads
Endothelial colony-forming cells (ECFCs), also termed late outgrowth endothelial cells, are a well-defined circulating endothelial progenitor cell type with an established role in vascular repair. ECFCs have clear potential for cell therapy to treat ischaemic disease, although the precise mechanism(s) underlying their response to hypoxia remains ill-defined.
In this study, we isolated ECFCs from umbilical cord blood and cultured them on collagen. We defined the response of ECFCs to 1% O2 exposure at acute and chronic time points.
In response to low oxygen, changes in ECFC cell shape, proliferation, size and cytoskeleton phenotype were detected. An increase in the number of senescent ECFCs also occurred as a result of long-term culture in 1% O2. Low oxygen exposure altered ECFC migration and tube formation in Matrigel®. Increases in angiogenic factors secreted from ECFCs exposed to hypoxia were also detected, in particular, after treatment with placental growth factor (PlGF). Exposure of cells to agents that stabilise hypoxia-inducible factors such as dimethyloxalylglycine (DMOG) also increased PlGF levels. Conditioned medium from both hypoxia-treated and DMOG-treated cells inhibited ECFC tube formation. This effect was reversed by the addition of PlGF neutralising antibody to the conditioned medium, confirming the direct role of PlGF in this effect.
This study deepens our understanding of the response of ECFCs to hypoxia and also identifies a novel and important role for PlGF in regulating the vasculogenic potential of ECFCs.
KeywordsHypoxia Endothelial progenitor cells Endothelial colony-forming cells Placental growth factor Senescence Migration
cAMP response element-binding protein
Endothelial colony-forming cell
Endothelial nitric oxide synthase
Endothelial progenitor cell
Focal adhesion kinase
Glucose transporter 1
Hypoxia inducible factor 1 alpha
Hypoxia inducible factor 2 alpha
Mitogen-activated protein kinase
Melanoma metastasis-associated surface molecule
Nuclear factor kappa-light-chain-enhancer of activated B cells
Outgrowth endothelial cell
Platelet endothelial cell adhesion molecule
Placental growth factor
Solute carrier family 2, facilitated glucose transporter member 1
Vascular endothelial growth factor
Vascular endothelial growth factor receptor 2
Since the first description of endothelial progenitor cells (EPCs) in 1997 as bone marrow-derived vascular precursors with reparative potential , there has been considerable interest in their utility for cell-based therapy of ischaemic vasculopathies. “EPC” refers to a broad range of vascular progenitors characterised using diverse cell surface markers and functional endpoints. Endothelial colony-forming cells (ECFCs), also known as late EPCs or outgrowth endothelial cells (OECs), are a subset of circulating EPCs with the ability to differentiate into endothelial cells and mediate vascular repair . When isolated, ECFCs have significantly higher proliferative capacity compared with mature endothelial cells, and they maintain their endothelial progenitor phenotype during long-term ex-vivo expansion . ECFCs are also capable of supporting vascular repair in vivo by integration into pre-existing vasculature, significantly reducing areas of ischaemia in murine models of retinopathy, myocardial infarction and stroke .
ECFCs have potential for use as cell-based therapy to treat ischaemic diseases by aiding vascular repair as well as establishing new vasculature . However, the function and number of ECFCs and other EPC subtypes have been reported to be impaired in a range of vascular disease states such as diabetes [6, 7], cardiovascular disease , preeclampsia  and vascular development in premature infants . The number and function of ECFCs has also been shown to be impaired in low birth weight infants , a patient cohort at risk of retinal ischaemia in infancy and cardiovascular disease in adulthood. Accelerated senescence in premature ECFCs as a result of decreased SIRT1 expression was also demonstrated recently . Therefore, it is important to understand what happens when ECFCs enter a hypoxic environment and what molecular cues are required to stimulate ECFC-mediated vascular repair.
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family that has been demonstrated to promote angiogenesis both independently and synergistically via heterodimer formation with VEGF-A to activate Flt1/VEGF receptor-1 signalling . PlGF also binds to the neuropilin-1/VEGF165 receptor and stimulates angiogenesis . Since its discovery in 1991 , PlGF has been associated with a number of disease states  including ischaemia , cardiovascular disease , cancer , arthritis  and preeclampsia . Recent reports have revealed that there is increased secretion of PlGF from ECFCs isolated from end-stage renal failure patients  while in-vitro exposure to PlGF can enhance tubulogenic function in ECFCs . These findings suggest that PlGF may have an important if ill-defined role in normal ECFC vasoreparative function. The signalling and functional responses of ECFCs exposed to PlGF remains to be elucidated, especially in the context of vascular insufficiency and hypoxia encountered by cells as they home to areas of localised tissue damage . In this study, we define the effects of acute and chronic hypoxia on ECFCs in the absence of other confounding factors. In response to low oxygen, we observed changes in ECFC cell size, shape, cytoskeletal structure and proliferative potential. Low oxygen altered ECFC scratch wound repair and in-vitro tube formation in Matrigel®. Of particular interest, we observed increased levels of PlGF secreted from ECFCs exposed to hypoxia and dimethyloxalylglycine (DMOG), a HIF stabilising agent. Conditioned medium from these cells inhibited tube formation in fresh ECFCs. This effect was reversed by neutralising antibodies against PlGF, confirming its central role in this effect. Improved knowledge of how ECFCs respond to low oxygen in vitro will aid understanding of how they may adapt their function to aid vascular repair in ischaemic diseases.
ECFC isolation, in-vitro culture and hypoxia exposure
ECFCs were isolated from umbilical cord blood of full-term neonates. Mononuclear cells (MNCs) were obtained by density gradient fractionation, re-suspended in complete medium (EGM-2; Lonza) supplemented with 10% FBS and seeded on 24-well culture plates pre-coated with rat tail collagen type 1 (BD Biosciences) at a density of 1 × 107 cells/ml. Colonies typically appeared within 2–3 weeks, and ECFC clones were typically cultured for >20 passages. A humidified, temperature-controlled hypoxia chamber (Coy Laboratories) was used to maintain cells in 1% O2. Culture media were preconditioned to 1% O2 prior to use to ensure instantaneous hypoxia exposure and the temperature was maintained at 37 °C. A Casy cell counter-analyser (Roche) was used for cell counts, viability and cellular size assessment.
Cells were fixed in 4% (w/v) paraformaldehyde for 20 min at room temperature. Following PBS washes, cells were permeabilised with 0.1% Triton X-100 for 10 min at RT and then blocked in 1% bovine serum albumin (BSA) for 2 h in PBS before overnight incubation in primary antibody at 4 °C. After washing with PBS, cells were incubated with appropriate secondary antibody for 1 h at RT and imaged under a confocal fluorescence scanning microscope (Nikon). Primary antibodies phalloidin (Invitrogen) and vinculin (Sigma-Aldrich) were used to stain F-actin and focal adhesion complexes respectively. Anti-mouse Alexa Fluor 568 IgG (Invitrogen) was used as secondary antibody. Mounting medium contained the nuclear stain DAPI (Vectashield; Vector Laboratories).
For staining, 5 × 105 ECFCs were used per sample. Cells were filtered using cell strainers with a 35-μm nylon mesh (BD Falcon; BD Biosciences), re-suspended in 100 μl PBS buffer and incubated with respective antibodies for 45 min at 4 °C. Antibodies reactive to CD31 (platelet endothelial cell adhesion molecule (PECAM)), CD45 (protein tyrosine phosphatase receptor type C), CD14 (monocyte differentiation antigen; eBioscience) and CD146 (melanoma cell adhesion molecule; BD Biosciences) were utilised. After staining, cells were washed in PBS and finally resuspended in 1 ml PBS for analysis using an Attune® Acoustic Focusing Flow Cytometer (Invitrogen Life Technologies). At least 20,000 events were acquired for each sample. Respective isotype controls were used to determine accurate settings for data analysis.
Protein extraction and western blotting
Protein was extracted from ECFCs using ice-cold RIPA containing protease and phosphatase inhibitors as described previously. Twenty micrograms of protein was resolved by electrophoresis through 10% SDS polyacrylamide gel and electro-transferred onto PVDF membrane (Millipore). The membranes were blocked for 1 h at RT with 3% (w/v) non-fat dry milk in Tris-buffered saline with 0.1% Tween-20 (TBS-T). After blocking, the membranes were incubated overnight at 4 °C with primary antibodies reactive to HIF-1α (#610958; BD Biosciences) and HIF-2α (R&D Systems). After three washes with TBS-T, the membranes were incubated for 1 h with their respective HRP-conjugated secondary antibodies (Santa Cruz). Three TBS-T washes were carried out before the protein bands were detected using ECL (Merck Millipore). Membranes were re-probed with β-actin (Cell Signaling Technology) as a housekeeping gene to ensure equal loading.
Scratch wound repair assay
ECFC viability was determined using the Cell Counting Kit-8 (CCK-8; Sigma) as per the manufacturer’s instructions. Cells were seeded in 96-well collagen-coated plates (1 × 104 cells/well). Cells were treated for 24 h with 100 ng/ml human recombinant PlGF (R&D Systems) or vehicle (4 mM HCl 0.1% BSA). Absorbance was measured at 450 nm using an Omega plate reader.
A proteome profiler human angiogenesis array (R&D Systems) was used to analyse the secretion of angiogenic cytokines from ECFCs. Cells were maintained in serum-free medium in 21 and 1% O2 for 24 h, in accordance with the manufacturer’s instructions. ImageJ image analysis software was used to calculate densitometry and all results were normalised to a positive control. PlGF levels in cell culture supernatant were measured using a PlGF-specific ELISA (R&D Systems) according to the manufacturer’s instructions.
ECFCs were grown in complete media (EGM-2; Lonza) and treated with either dimethylsulfoxide (DMSO, vehicle) or 1 mM DMOG (Sigma-Aldrich) for 24 h. At harvest, media were removed and stored at –80 oC for analysis, after which the cells were washed in ice-cold PBS prior to further analysis by western blot analysis. PlGF levels in cell culture supernatant were measured using a PlGF-specific ELISA (R&D Systems) according to the manufacturer’s instructions.
ECFCs were labelled using a fluorescence membrane labelling kit (PKH; Sigma) or Calcein AM dye (Molecular Probes) according to the manufacturer's protocol. Between 8 × 104 and 1 × 105 labelled ECFCs were re-suspended in basement membrane matrix (Matrigel®; BD Biosciences). Fifty-microlitre aliquots were spotted onto four-well plates. After polymerisation, the spots were covered in endothelial cell growth medium (EGM-2; Lonza) or a 1:1 ratio of EGM-2 and conditioned media. Wells were assessed for the presence of tube-like structures after 24, 48 and 72 h, and were imaged using a confocal scanning microscope (Nikon). For PlGF neutralising experiments, ECFCs (7.5 × 105 cells) were mixed with conditioned medium collected from previously treated ECFCs exposed to vehicle or DMOG (1 mM) and resuspended in basement membrane Matrix (Matrigel®). Next, 50-μl aliquots were spotted onto a 24-well plate and allowed to polymerise. After polymerisation, spots were covered in conditioned medium from vehicle or DMOG-treated cells in the presence of a PlGF neutralising antibody (MAB264; R&D Systems) or an isotype IgG control (Sigma). Matrigel® spots were labelled with Calcein AM dye (Molecular Probes) prior to imaging. Wells were assessed for the presence of tube-like structures after 24 h, and imaged using a confocal scanning microscope (Nikon). The vascular tube area was quantified using NIS Elements software (Nikon).
Reverse-transcription and real-time PCR
Total RNA was isolated using an RNeasy Mini Kit (Qiagen). cDNA was synthesised from 500 ng RNA using Superscript III (Invitrogen). Semi-quantitative real-time PCR was performed using gene-specific Real Time ready Custom Single assays for ANGPTL4, SLC2A1 and housekeeping genes β-actin and 18S (Roche). Relative quantitative values were obtained using the ∆∆Ct method.
ECFCs were grown on collagen-coated glass coverslips prior to senescence analysis. β-Galactosidase activity was detected using the Senescence β-galactosidase Staining Kit (Cell Signalling Technology) according to the manufacturer’s instructions. The cell monolayer was imaged using a phase contrast microscope (Nikon). The percentage of positively stained cells was quantified using ImageJ image analysis software.
Data were analysed using Student’s two-tailed paired or unpaired t test or ANOVA and were plotted as mean ± standard deviation (SD) unless otherwise indicated.
ECFCs remain a promising candidate for cell therapy to treat tissue ischaemia. However, robust characterisation of ECFC cell behaviour in the target tissues and disease-related microenvironments is required as these cells move towards therapy. In this study, we have defined the response of ECFCs to hypoxia exposure, one of the main factors associated with vascular insufficiency and tissue ischaemia. The HIF transcription factors are considered master regulators of hypoxia, having an established role in the cellular response to oxygen deprivation, and are of critical importance in hypoxia-driven angiogenesis by controlling the expression of many genes required for the process . In response to a graded decrease in O2, HIF-1α stabilisation was detected in ECFCs at the lower O2 levels of 3 and 1% with no HIF stabilisation detectable at the higher oxygen concentrations of 5 and 10% (Fig. 1). Similarly, in a study investigating the effect of low oxygen levels on ECFCs and MSCs, Hofmann et al.  reported that while MSCs and fibroblasts are very sensitive to lowering oxygen concentration HIF-1α stabilisation only occurred at 1% O2 levels. Accumulation of HIF-1α occurred within 5 min in these cells (Fig. 1b). These findings are important because the physiological oxygen tension varies widely between different cell types and tissues. For example, alveoli have a physiological oxygen concentration of approximately 14.5% (approximately 110 mmHg), while the brain has a much lower physiological oxygen percentage in the region of 4.4% (34 mmHg) . In fact, culturing ECFCs in ambient 21% O2 may actually elevate the physiological oxygen tension above baseline, where key stem cell niches such as the bone marrow would normally experience a much lower physiological oxygen tension of around 6.4% (49 mmHg) . Other groups have found that culturing induced pluripotent stem cells (iPS) and mesenchymal stem cells (MSCs) at low oxygen concentrations provides enhanced functional outcomes [31, 32]. While not within the remit of this study, future studies will probably define the optimum oxygen concentration for ex-vivo ECFC culture. Maintenance in an oxygen concentration likely to be experienced in vivo may improve the therapeutic potential of these cells for clinical use. For this study, we chose 1% O2 based on robust stabilisation of HIF-1α and HIF2α, along with HIF-1α nuclear translocation and hypoxia-dependent gene expression changes that were detected under these conditions (Figs. 1 and 2).
ECFCs cultured in 1% O2 for 24–72 h displayed changes in their actin cytoskeleton (Fig. 3), as well as cell doubling, increased cell size and staining for senescence markers (Fig. 4). Increased filamentous actin, along with the appearance of focal adhesions at the end of actin stress fibres, suggested that hypoxia was inducing enhanced ECFC adherence to the cell culture dish (Fig. 3). One interpretation of these data is that when ECFCs are recruited to the ischaemic/hypoxic tissue, they need to attach to the extracellular matrix in close proximity to either damaged blood vessels or avascular regions. These data were supported by reduced ECFC scratch wound repair in 1% O2 versus 21% O2 (Fig. 5). Reductions in ECFC chemotaxis/migration in response to low oxygen have been reported by both the Yoder and Strunk groups [29, 33], while the Yoder group also detected an increase in hypoxia-mediated tube formation in ECFCs, albeit at an earlier time point than our study (6 h versus 72 h, Fig. 4d ). Hofmann et al.  also report a decrease in tube formation in ECFCs when exposed to 1% O2. In vascular smooth muscle cells, HIF-1α expression decreased cell migration and adherence to the ECM, with no evident changes in vincullin or focal adhesion kinase (FAK) localisation . Hypoxia increased MSC migration, probably via VEGF-mediated phosphorylation of FAK and activation of MAPK and eNOS signalling . Hypoxia increased αvβ3 integrin cell surface expression and cell adhesion in trophoblast stem cells . Together with our results, these data suggest that there may be cell-type specific responses to low oxygen, with ECFCs demonstrating increased adhesiveness and decreased proliferation and migration, perhaps to ensure their effective engraftment to the ischaemic tissue in vivo. Consistently, we have identified that exposure of ECFCs to hypoxia decreases the expression of CD34, a marker of “stemness”, which suggests that ECFCs in the hypoxic niche become more endothelial-like to perhaps improve their ability to repair damaged endothelium (data not shown).
One of the key findings of this study was the increased secretion of PlGF by ECFCs (Fig. 6). Despite the robust increase in PlGF protein expression in 1% O2 or in response to DMOG, an inhibitor of HIF prolyl hydroxylases , previous analysis of the PlGF promoter and enhancer regions did not identify any the putative binding sites for HIFs (hypoxia response elements (HREs)) [38, 39, 40]. Consistent with data from Xiang et al. , we did not detect any increase in PlGF RNA in hypoxia-exposed ECFCs. In contrast, overexpression of HIF-1α has been reported by others to augment the expression of PlGF in both endothelial cells [42, 43, 44] and primary cardiac and vascular cells , indicating that HIFs may well have a role to play in PlGF expression. A recent report identified novel HIF-1α HREs in intron 2 of the PlGF gene, and highlighted chromatin remodelling via histone H3 and H4 acetylation as a key element in HIF1α-mediated PlGF upregulation [44, 46]. Other transcription factors such as NFκB and CREB are also stabilised under low oxygen conditions, and may play a role in PlGF upregulation [41, 42, 45, 46]. PlGF has been reported to enhance angiogenic signalling by acting synergistically with VEGF to increase signalling via the receptor VEGFR2 [47, 48] while also maintaining the ability to induce angiogenic signalling independent of VEGF . Others have identified that PlGF may increase blood vessel formation via monocyte recruitment and paracrine signalling to endothelial cells [41, 44]. Increased PlGF secretion from ECFCs coincided with a delay in in-vitro tube formation in Matrigel® (Fig. 8b, c). Neutralising antibodies against PlGF rescue ECFC tube formation in Matrigel® (Fig. 9). Thus, hypoxia/HIF-mediated increases in PlGF secretion from ECFCs may inhibit tube formation and vasculogenesis.
Our data suggest that, in vitro, in the absence of VEGF, PlGF may not be driving ECFC tube formation, and heterodimers of PlGF and VEGF may be the active moieties. This is somewhat surprising, given the previously described pro-angiogenic activity of PlGF . It remains to be determined whether PlGF released from ECFCs in the hypoxic niche would have both an autocrine and a paracrine function, and what the relative balance of these functions might be. We can also speculate that PlGF from chronically hypoxia-exposed ECFCs may function to attract monocytes, pericytes or mural cells to stabilise the vascular niche. PlGF may also be secreted from the cells of the tissue parenchyma in ischaemic tissue. Alternatively, a paracrine source of VEGF or other factor from cells such as pericytes or endothelial cells may be required to trigger new blood vessel formation. ECFCs have been demonstrated to act as paracrine mediators, modulating MSC regeneration potential prior to the establishment of neovascularisation and blood perfusion, ultimately enabling extensive engraftment and long-term differentiation of transplanted MSCs . Recent work by Xiang et al. [41, 44] supports the idea of a paracrine role for PlGF secreted by endothelial cells in vascular repair.
This study deepens our understanding of the response of ECFCs to hypoxia and also addresses important questions regarding the role of PlGF and chronic hypoxia in influencing the neovascular potential of ECFCs. Further studies will be required to determine whether ex-vivo pre-conditioning of ECFCs, by either hypoxia or PlGF, or manipulation of PlGF expression in vivo may be useful tools to augment ECFC neovascularisation for the future treatment of ischaemic disease.
The authors thank Lynsey-Dawn Allen and other technical staff at the Centre of Experimental Medicine for technical assistance.
This work was supported by Action Medical Research UK. Work in the laboratory of Derek Brazil is supported by the Wellcome Trust, Northern Ireland Kidney Research Fund and DEL NI.
Availability of data and materials
The datasets for and/or analysed during the current study are available from the corresponding author on reasonable request.
MBH was responsible for conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing. IHAA was responsible for collection and assembly of data, data analysis and interpretation. CLO, EH, MHL and TS were responsible for collection and assembly of data. RM, SC, BR, EM, DS and AWS were responsible for provision of study material or patients. DPB was responsible for conception and design, data analysis and interpretation, and manuscript writing. All authors have been involved in revising and approving the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethical approval and consent to participate
The Office for Research Ethics Committees Northern Ireland gave full approval for this study (08/NIR02/02). All participants gave written and informed consent prior to collection of blood from umbilical cords.
- 5.Lois N, McCarter RV, O'Neill C, et al. Endothelial progenitor cells in diabetic retinopathy. Front Endocrinol (Lausanne). 2014;5:44.Google Scholar
- 16.Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med. 2012;2:901156.Google Scholar
- 31.Liu SP, Li YX, Xu J, et al. An improved method for generating integration-free human induced pluripotent stem cells. J Exp Hematol. 2014;22:580–7.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.